Dr. Tae Han KimSamsung Biologics Reports Strong Q2 Result in Light of COVID-19Samsung Biologics is a fully integrated CDMO that offers one-stop services in development, manufacturing and biosafety testing. With the…Sep 24, 2020Sep 24, 2020
Dr. Tae Han KimSamsung Biologics to add fourth plant with growing demandIncheon, S. Korea, 11 Aug 2020 — Samsung Biologics (KRX: 207940.KS) today held an online press conference to announce its plans to break…Aug 11, 2020Aug 11, 2020
Dr. Tae Han KimGrowing Samsung’s Position within the Industry With Samsung Biologics CEO, Dr.Dr. Tae Han Kim, the founding CEO of Samsung Biologics, began his career with Samsung nearly 40 years ago, working from the ground level…Jul 15, 2020Jul 15, 2020
Dr. Tae Han KimSamsung Biologics Q1 Results Show PerseveranceOn Monday, April 20 th, it was announced that Samsung Biologics (KRX: 207940.KS) released its Q1 earnings results. The company presented…May 21, 2020May 21, 2020
Dr. Tae Han KimCOVID-19 Update from CEO of Samsung Biologics, Tae Han KimA message from the CEOMay 6, 2020May 6, 2020